Patents by Inventor Timothy M. Willson

Timothy M. Willson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ORPHAN NUCLEAR RECEPTOR
    Publication number: 20120283412
    Abstract: The present invention relates to a novel human orphan nuclear receptor that binds to a cytochrome P-450 monooxygenase (CYP) promoter and that is activated by compounds that induce CYP gene expression. The invention further relates to nucleic acid sequences encoding such a receptor, to methods of making the receptor and to methods of using the receptor and nucleic acid sequences encoding same. The invention also relates to non-human animals transformed to express the human receptor and to methods of using such animals to screen compounds for drug interactions and toxicities.
    Type: Application
    Filed: July 16, 2012
    Publication date: November 8, 2012
    Inventors: Steven A. Kliewer, Stacey A. Jones, Timothy M. Willson
  • Orphan nuclear receptor
    Patent number: 8221991
    Abstract: The present invention relates to a novel human orphan nuclear receptor that binds to a cytochrome P-450 monooxygenase (CYP) promoter and that is activated by compounds that induce CYP gene expression. The invention further relates to nucleic acid sequences encoding such a receptor, to methods of making the receptor and to methods of using the receptor and nucleic acid sequences encoding same. The invention also relates to non-human animals transformed to express the human receptor and to methods of using such animals to screen compounds for drug interactions and toxicities.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: July 17, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Steven A. Kliewer, Stacey A. Jones, Timothy M. Willson
  • Orphan Nuclear Receptor
    Publication number: 20110059478
    Abstract: The present invention relates to a novel human orphan nuclear receptor that binds to a cytochrome P-450 monooxygenase (CYP) promoter and that is activated by compounds that induce CYP gene expression. The invention further relates to nucleic acid sequences encoding such a receptor, to methods of making the receptor and to methods of using the receptor and nucleic acid sequences encoding same. The invention also relates to non-human animals transformed to express the human receptor and to methods of using such animals to screen compounds for drug interactions and toxicities.
    Type: Application
    Filed: September 8, 2010
    Publication date: March 10, 2011
    Inventors: Steven A. Kliewer, Stacey A. Jones, Timothy M. Willson
  • Pregnane X receptor method
    Patent number: 7238491
    Abstract: The present invention relates to a novel human orphan nuclear receptor that binds to a cytochrome P-450 monooxygenase (CYP) promoter and that is activated by compounds that induce CYP gene expression. The invention further relates to nucleic acid sequences encoding such a receptor, to methods of making the receptor and to methods of using the receptor and nucleic acid sequences encoding same. The invention also relates to non-human animals transformed to express the human receptor and to methods of using such animals to screen compounds for drug interactions and toxicities.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: July 3, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: Steven A. Kliewer, Stacey A. Jones, Timothy M. Willson
  • Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
    Patent number: 5994554
    Abstract: The present invention provides radiolabeled 5-{4-[2-(Methyl-pyridine-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dion e. In another aspect, the present invention provides a method for determining whether a compound does or does not interact directly with PPAR-gamma, comprising the step of specifically binding a radiolabeled compound of this invention to the ligand binding domain of PPAR-gamma.
    Type: Grant
    Filed: December 9, 1998
    Date of Patent: November 30, 1999
    Assignee: Glaxo Wellcome Inc.
    Inventors: Steven Anthony Kliewer, Jurgen M. Lehmann, Timothy M. Willson
  • Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
    Patent number: 5902726
    Abstract: The present invention provides activator compounds, including agonists, to the peroxisome proliferator-activated receptor gamma. Particular PPAR.gamma. activators are set forth, as are a pharmaceutical composition for treating diabetes, non-insulin-dependent diabetes mellitus, cardiovascular disorders, and methods for such treatment.
    Type: Grant
    Filed: February 25, 1998
    Date of Patent: May 11, 1999
    Assignee: Glaxo Wellcome Inc.
    Inventors: Steven Anthony Kliewer, Jurgen M. Lehmann, Timothy M. Willson
  • Substituted pyridines, their preparation, formulations and use in dementia
    Patent number: 5346906
    Abstract: Pyridines, substituted by a quinuclidine and a substituent of low lipophilicity or a hydrocarbon substituent, their salts and prodrugs, and formulations thereof are useful in the treatment of neurodegenerative disorders such as dementia. The compounds can be synthesized by methods analogous to these known in the art.
    Type: Grant
    Filed: November 16, 1992
    Date of Patent: September 13, 1994
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Raymond Baker, John Saunders, Timothy M. Willson, Janusz J. Kulagowski